Published in J Bone Miner Res on July 23, 2010
Effects of Arzoxifene on Bone Fractures and Incidence of Breast Cancer | NCT00088010
Atypical hyperplasia of the breast--risk assessment and management options. N Engl J Med (2015) 3.57
Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. Lancet (2013) 3.31
Future directions in cancer prevention. Nat Rev Cancer (2012) 1.62
The discovery and development of selective estrogen receptor modulators (SERMs) for clinical practice. Curr Clin Pharmacol (2013) 1.44
Current strategies for the prevention of breast cancer. Breast Cancer (Dove Med Press) (2014) 0.93
Correlation between 25-hydroxyvitamin D levels and latitude in Brazilian postmenopausal women: from the Arzoxifene Generations Trial. Osteoporos Int (2013) 0.89
Molecular cancer prevention: Current status and future directions. CA Cancer J Clin (2015) 0.86
Exemestane for breast cancer prevention: a critical shift? Cancer Discov (2012) 0.85
Tamoxifen vs Raloxifene vs Exemestane for Chemoprevention. Curr Breast Cancer Rep (2012) 0.82
Osteoporosis and cancer. Curr Osteoporos Rep (2013) 0.80
Raloxifene and desmethylarzoxifene block estrogen-induced malignant transformation of human breast epithelial cells. PLoS One (2011) 0.79
Arzoxifene versus raloxifene: effect on bone and safety parameters in postmenopausal women with osteoporosis. Osteoporos Int (2011) 0.78
Preventative therapies for healthy women at high risk of breast cancer. Cancer Manag Res (2014) 0.78
Association of back pain with hypovitaminosis D in postmenopausal women with low bone mass. BMC Musculoskelet Disord (2013) 0.77
Medical prevention of breast cancer. Breast Care (Basel) (2014) 0.77
Is there a future for selective estrogen-receptor modulators in osteoporosis? Ther Adv Musculoskelet Dis (2012) 0.77
Chemoprevention of Breast Cancer: The Paradox of Evidence versus Advocacy Inaction. Cancers (Basel) (2012) 0.76
Novel Promising Estrogenic Receptor Modulators: Cytotoxic and Estrogenic Activity of Benzanilides and Dithiobenzanilides. PLoS One (2016) 0.75
Breast-related effects of selective estrogen receptor modulators and tissue-selective estrogen complexes. Breast Cancer Res (2014) 0.75
Multiplex genome engineering using CRISPR/Cas systems. Science (2013) 55.53
Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet (2006) 19.03
RNA-guided editing of bacterial genomes using CRISPR-Cas systems. Nat Biotechnol (2013) 15.51
Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med (2009) 13.57
A variant in CDKAL1 influences insulin response and risk of type 2 diabetes. Nat Genet (2007) 13.28
Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. Nat Genet (2007) 12.65
Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet (2008) 10.87
Health-related quality of life in total hip and total knee arthroplasty. A qualitative and systematic review of the literature. J Bone Joint Surg Am (2004) 7.59
Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet (2012) 7.59
Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med (2014) 6.56
The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med (2004) 6.55
Multiple genetic loci for bone mineral density and fractures. N Engl J Med (2008) 6.35
Refining the impact of TCF7L2 gene variants on type 2 diabetes and adaptive evolution. Nat Genet (2007) 5.88
Lasofoxifene in postmenopausal women with osteoporosis. N Engl J Med (2010) 5.60
Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nat Genet (2012) 5.48
Efficacy and safety of strontium ranelate in the treatment of knee osteoarthritis: results of a double-blind, randomised placebo-controlled trial. Ann Rheum Dis (2012) 4.81
Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res (2004) 4.04
The effects of tibolone in older postmenopausal women. N Engl J Med (2008) 3.96
Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease. N Engl J Med (2005) 3.57
Precise determination of the diversity of a combinatorial antibody library gives insight into the human immunoglobulin repertoire. Proc Natl Acad Sci U S A (2009) 3.56
Fracture risk and zoledronic acid therapy in men with osteoporosis. N Engl J Med (2012) 3.51
New sequence variants associated with bone mineral density. Nat Genet (2008) 3.43
Peripheral adiposity exhibits an independent dominant antiatherogenic effect in elderly women. Circulation (2003) 3.37
Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. Lancet (2013) 3.31
FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis. Science (2011) 3.16
Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis: a comprehensive meta-analysis. Arch Intern Med (2003) 3.07
Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis Rheum (2006) 2.82
Genome-wide association study identifies sequence variants on 6q21 associated with age at menarche. Nat Genet (2009) 2.58
Nonsense mutation in the LGR4 gene is associated with several human diseases and other traits. Nature (2013) 2.55
Relationship between osteoporosis and cardiovascular disease in postmenopausal women. J Bone Miner Res (2005) 2.49
Gender-specific gene expression in post-mortem human brain: localization to sex chromosomes. Neuropsychopharmacology (2004) 2.48
Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group. Cancer Treat Rev (2008) 2.48
Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension. J Bone Miner Res (2012) 2.34
Enlarged waist combined with elevated triglycerides is a strong predictor of accelerated atherogenesis and related cardiovascular mortality in postmenopausal women. Circulation (2005) 2.30
Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study. J Bone Miner Res (2004) 2.23
The effect of oral calcitonin on cartilage turnover and surface erosion in an ovariectomized rat model. Arthritis Rheum (2007) 2.22
Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides, unassisted by transfection reagents. Nucleic Acids Res (2009) 2.22
Common variants at VRK2 and TCF4 conferring risk of schizophrenia. Hum Mol Genet (2011) 2.21
The incidence of osteonecrosis of the jaw in patients receiving 5 milligrams of zoledronic acid: data from the health outcomes and reduced incidence with zoledronic acid once yearly clinical trials program. J Am Dent Assoc (2010) 2.19
Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab (2002) 2.15
Natural stimuli evoke dynamic sequences of states in sensory cortical ensembles. Proc Natl Acad Sci U S A (2007) 2.11
Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure. J Bone Miner Res (2008) 2.04
Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate. Bone (2007) 1.97
Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures. J Bone Miner Res (2012) 1.92
Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years. J Clin Endocrinol Metab (2006) 1.88
Are nonresorbing osteoclasts sources of bone anabolic activity? J Bone Miner Res (2007) 1.82
Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis. J Clin Endocrinol Metab (2002) 1.82
Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res (2005) 1.81
Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res (2008) 1.79
Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women. J Natl Cancer Inst (2010) 1.79
Early postmenopausal hormone therapy may prevent cognitive impairment later in life. Menopause (2005) 1.77
A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. Clin Ther (2007) 1.73
Segmenting articular cartilage automatically using a voxel classification approach. IEEE Trans Med Imaging (2007) 1.73
Sequence variants in the CLDN14 gene associate with kidney stones and bone mineral density. Nat Genet (2009) 1.73
Suppression of elevated cartilage turnover in postmenopausal women and in ovariectomized rats by estrogen and a selective estrogen-receptor modulator (SERM). Menopause (2004) 1.66
The efficacy of glucosamine sulfate in osteoarthritis: financial and nonfinancial conflict of interest. Arthritis Rheum (2007) 1.65
Toward a roadmap in global biobanking for health. Eur J Hum Genet (2012) 1.65
Linkage of osteoporosis to chromosome 20p12 and association to BMP2. PLoS Biol (2003) 1.64
Efficacy and safety of oral strontium ranelate for the treatment of knee osteoarthritis: rationale and design of randomised, double-blind, placebo-controlled trial. Curr Med Res Opin (2012) 1.64
Prediction of clinicopathologic response of breast cancer to primary chemotherapy at contrast-enhanced MR imaging: initial clinical results. Radiology (2006) 1.60
The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension. J Clin Endocrinol Metab (2013) 1.60
Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab (2002) 1.59
Development of an Environmental Relative Moldiness index for US homes. J Occup Environ Med (2007) 1.59
Glucosamine sulfate reduces osteoarthritis progression in postmenopausal women with knee osteoarthritis: evidence from two 3-year studies. Menopause (2004) 1.57
A meta-analysis of the association of fracture risk and body mass index in women. J Bone Miner Res (2014) 1.56
Long-term effects of chondroitins 4 and 6 sulfate on knee osteoarthritis: the study on osteoarthritis progression prevention, a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum (2009) 1.54
Chemosensory cues to conspecific emotional stress activate amygdala in humans. PLoS One (2009) 1.54
Role of gastrointestinal hormones in postprandial reduction of bone resorption. J Bone Miner Res (2003) 1.52
Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch Intern Med (2004) 1.51
Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis. Calcif Tissue Int (2011) 1.50
Strategies for the prevention of hip fracture. Am J Med (2003) 1.50
An update on the antiestrogenic effect of smoking: a literature review with implications for researchers and practitioners. Menopause (2004) 1.49
Clinical evaluation of medicinal products for acceleration of fracture healing in patients with osteoporosis. Bone (2008) 1.48
Development of a highly automated and multiplexed targeted proteome pipeline and assay for 112 rat brain synaptic proteins. Proteomics (2015) 1.46
Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis. Bone (2008) 1.44
The morphologic left ventricle that requires training by means of pulmonary artery banding before the double-switch procedure for congenitally corrected transposition of the great arteries is at risk of late dysfunction. J Thorac Cardiovasc Surg (2008) 1.43
Cartilage degradation is fully reversible in the presence of aggrecanase but not matrix metalloproteinase activity. Arthritis Res Ther (2008) 1.43
Controlled whole body vibration to decrease fall risk and improve health-related quality of life of nursing home residents. Arch Phys Med Rehabil (2005) 1.42
Phonology and reading: a response to Wang, Trezek, Luckner, and Paul. Am Ann Deaf (2009) 1.42
Analysis of a key regulatory region upstream of the Myf5 gene reveals multiple phases of myogenesis, orchestrated at each site by a combination of elements dispersed throughout the locus. Development (2003) 1.41
The disease modifying osteoarthritis drug (DMOAD): Is it in the horizon? Pharmacol Res (2008) 1.38
Adiposity, hormone replacement therapy use and breast cancer risk by age and hormone receptor status: a large prospective cohort study. Breast Cancer Res (2012) 1.37
Reduced risk of back pain following teriparatide treatment: a meta-analysis. Osteoporos Int (2005) 1.36
Gene expression patterns for doxorubicin (Adriamycin) and cyclophosphamide (cytoxan) (AC) response and resistance. Breast Cancer Res Treat (2006) 1.32
Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study. J Bone Miner Res (2008) 1.32
Relationship between bone mineral density changes and fracture risk reduction in patients treated with strontium ranelate. J Clin Endocrinol Metab (2007) 1.32
Effects of denosumab on bone turnover markers in postmenopausal osteoporosis. J Bone Miner Res (2011) 1.32
Identification of progressors in osteoarthritis by combining biochemical and MRI-based markers. Arthritis Res Ther (2009) 1.30
Extracellular matrix remodeling: the common denominator in connective tissue diseases. Possibilities for evaluation and current understanding of the matrix as more than a passive architecture, but a key player in tissue failure. Assay Drug Dev Technol (2012) 1.30
Common genetic variants in prostate cancer risk prediction--results from the NCI Breast and Prostate Cancer Cohort Consortium (BPC3). Cancer Epidemiol Biomarkers Prev (2012) 1.29
Yearly zoledronic acid in postmenopausal osteoporosis. N Engl J Med (2007) 1.29
Viagra use in a community-recruited sample of men who have sex with men, San Francisco. J Acquir Immune Defic Syndr (2003) 1.29
A P3G generic access agreement for population genomic studies. Nat Biotechnol (2013) 1.28
When is door-to-balloon time critical? Analysis from the HORIZONS-AMI (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction) and CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) trials. J Am Coll Cardiol (2010) 1.28